Skip to content
DataLookout
Menu

TIGER-1NCT07767110

Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Lead sponsor: NanOlogy, LLC to NanOlogy, LLC (doing business as Intryx Therapeutics, LLC)
    • Eligibility criteria changed
    • Secondary endpoints: details revised at 2 of 5 entries
  2. Notable Primary endpoint(s) modified
    • Eligibility criteria expanded, about 51 words
    • Secondary endpoints: details revised at 4 of 5 entries
    • Study description expanded, about 7 words
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)
Timeframe: Day 1 to Week 24

Secondary (5)

Objective Response Rate (ORR)
Progression-Free Survival (PFS)
Overall Survival (OS)
Concentration of Cisplatin in the Systemic Circulation Post-infusion
Concentration of Cisplatin in the Cerebrospinal Fluid (CSF) Post-infusion

Arms and interventions

LSAM-Cisplatin 6 mg/mLExperimental

Phase 1 (Dose Escalation): Intratumoral infusion of LSAM-Cisplatin 6 mg/mL using sequential, dose escalating cohorts. Phase 2 (Dose Expansion): Intratumoral infusion of LSAM-Cisplatin 6 mg/mL at the recommended Phase 2 dose (RP2D).

Drugs: LSAM-Cisplatin